Skip to main content

News

You are here

UM Ventures News

UM Ventures, Baltimore Newsletter | Summer 2026

Have an invention?Disclose it to the UM Ventures, Baltimore team. Featured Article An Internal Perspective of the Achievements of UMB Student Entrepreneurs Linda Petrillo, PhD, Research and Alliance Officer at University of Maryland, Baltimore (UMB), shares her... read more

Patent Awards | January - March 2026

Self-Expanding CannulaU.S. patent issued January 6, 2026 UMB inventors: Zhongjun Jon Wu, PhD; Bartley Griffith, MD Methods for Preventing Acute Kidney InjuryU.S. Continuation-in-Part issued January 6, 2026 UMB inventors: Mordecai P. Blaustein, MD; John M. Hamlyn, PhD; Stephen S. Gottlieb, MD... read more

A Legacy to UMB’s Research Commercialization: Gail Knott

For more than two decades, Gail Knott has been a central figure in the University of Maryland, Baltimore’s (UMB) Office of Research and Development (ORD), managing all aspects of technology transfer, including intellectual property (IP) and licensing compliance, commercial partnerships, and... read more

Inventor Spotlight: Yin Wang, PhD

Yin Wang, PhD, assistant professor in the University of Maryland School of Medicine’s Institute of Human Virology On the cutting edge of nanomedicine development, Yin Wang, PhD, assistant professor in the University of Maryland School of Medicine’s (UMSOM) Institute... read more

GlycoT Therapeutics

Founded in 2015 and based in Maryland, GlycoT Therapeutics is an emerging biotechnology company advancing next-generation biologics through precise glycoengineering. The joint University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP) startup company was built on... read more

Technology Transfer Guidance: UMB and VA Invention Management Agreement

More than 70 Veterans Affairs (VA) hospitals are located within five miles of a U.S. medical school. The Baltimore VA Medical Center is even closer, with a skybridge connecting it to the University of Maryland Medical Center, and more than 150 faculty members holding dual appointments between the... read more

An Internal Perspective of the Achievements of UMB Student Entrepreneurs

By Linda Petrillo, PhD, Research and Alliance OfficerAs I sat in the audience at Nucleate’s 5th DMV Activator Demo Day on May 22, 2026, at the Pava Marie LaPere Center for Entrepreneurship at Johns Hopkins University, it was immediately clear that the University of Maryland, Baltimore (UMB)... read more

University System of Maryland Momentum Fund Invests in Alchemity

BALTIMORE (July 14, 2026) — The University System of Maryland Momentum Fund (Momentum Fund) has joined Alchemity’s  Seed Financing round, alongside Blackbird Labs, Chesapeake Bay Seed Capital Fund, the Discovery Fund, District Angels, the Maryland Energy Innovation Accelerator through the Climate... read more

BioSpace: US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences’ Dual Signal Modulator for the Treatment of Duchenne Muscular Dystrophy

 Dual FDA designations support advancement of GEn1E’s novel oral precision therapy GEn-1123 for a rare devastating neuromuscular disease with critical unmet need PALO ALTO, Calif.--(BUSINESS WIRE)--GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven precision... read more

Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy

Series A financing from RA Capital supports advancement of Secretome’s neonatal cardiac progenitor cell (nCPC) platform and planned Phase 2 and Phase 3 clinical trials of STM-01 in Duchenne muscular dystrophy-associated cardiomyopathy Industry veteran David Lubner joins Secretome’s Board of... read more